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In this article, we examine the issues involved if national or sub-national programs are considering
extending post HPV vaccine introduction monitoring to include males. Vaccination programs are now
being extended to include males in some countries, in order to improve population level HPV infection
control and to directly prevent HPV-related disease in males such as anogenital warts and anal cancers.
Coverage and adverse events surveillance are essential components of post-vaccination monitoring.
Monitoring the impact of vaccination on HPV infection and disease in men raises some similar challenges
to monitoring in females, such as the long time frame until cancer outcomes, and also different ones
given that genital specimens suitable for monitoring HPV prevalence are not routinely collected for other
diagnostic or screening purposes in males. Thus, dedicated surveillance strategies must be designed; the
framework of these may be country-speciﬁc, dependent upon the male population that is offered vac-
cination, the health care infrastructure and existing models of disease surveillance such as STI networks.
The primary objective of any male HPV surveillance program will be to document changes in the pre-
valence of HPV infection and disease due to vaccine targeted HPV types occurring post vaccination. The
full spectrum of outcomes to be considered for inclusion in any surveillance plan includes HPV pre-
valence monitoring, anogenital warts, potentially pre-cancerous lesions such as anal squamous in-
traepithelial lesions (SIL), and cancers. Ideally, a combination of short term and long term outcome
measures would be included. Surveillance over time in speciﬁc targeted populations of men who have
sex with men and HIV-infected men (populations at high risk for HPV infection and associated disease)
could be an efﬁcient use of resources to demonstrate impact.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Worldwide human papillomaviruses (HPV) cause multiple
cancers and anogenital warts in men and women. By far cervical
cancer contributes the largest number of cases to the global bur-
den of HPV-related cancers annually. The main focus of global
vaccine programs has been prevention of cervical cancer, through
prevention of oncogenic HPV infection, the necessary cause of
squamous and glandular cervical carcinomas [1,2]. Currently manyan open access article under the C
n Program Register, Victorian
ia 8002, Australia.
rton).countries have two prophylactic HPV vaccines licensed (a bivalent
and a quadrivalent vaccine) that prevent infection with, and thus
disease due to, HPV16 and 18, the two oncogenic types that cause
most cancers [3,4]. In 2014, the US FDA licensed a 9-valent HPV
vaccine (Gardasil 9) with expanded coverage against ﬁve addi-
tional HPV types that cause cervical cancer. The 9-valent vaccine
has the potential to prevent up to 90% of cervical cancers world-
wide [5]. If broadly disseminated, the bivalent and quadrivalent
vaccines could potentially prevent over two-thirds of cervical
cancer cases globally [4] and the majority of HPV-related vulvar,
vaginal, and anal cancers in women.
With the growing recognition that HPV causes some cancers in
men (i.e., anal, oropharyngeal, oral, and penile cancers) there has
been increased interest in the potential to prevent other cancers inC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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vaccination [6]. The quadrivalent vaccine has demonstrated efﬁ-
cacy in males and is licensed for use in males, as is the 9-valent
vaccine. [7] Immunogenicity of the 9-valent vaccine in males was
shown to be non-inferior to that in same age females, providing
immunobridging to the female efﬁcacy trial in women aged 16–26
years. [7–9]. Some public HPV vaccine programs are now including
males, both to increase prevention of HPV infection in the popu-
lation through herd immunity and to provide a direct beneﬁt to
males in prevention of HPV-related diseases and cancers of men
[7,10]. These countries include Austria (recommended since 2011
but not funded until 2014) [11], Australia (commenced 2013) [12],
the US (commenced 2011) [13], and parts of Canada (Alberta, Nova
Scotia, British Columbia and Prince Edward Island) [14].
Worldwide, over 500,000 women develop cervical cancer
yearly, and approximately 40,000 HPV related cancers occur in
men, causing considerable personal and public health impact
[15,16]. At present, there are no recommended screening programs
for HPV-related cancers in men [17]. A particularly high risk po-
pulation are men who have sex with men (MSM) who have a
signiﬁcantly higher incidence of anal and other cancers than other
men or women [12,18,19]. Both men and women with HIV infec-
tion and other forms of immunosuppression are also at increased
risk of HPV–related cancers [20]. Anogenital warts, which are
caused by HPV 6 and 11 and prevented by the quadrivalent HPV
and the 9-valent HPV vaccines, are a signiﬁcant burden in both
men and women. A systematic review of 32 studies found that the
annual incidence of anogenital warts ranged from 160 to 289 per
100,000 [21].
Especially with HPV vaccination programs now being extended
to include males in some countries, there is a need to deﬁne best
practices for monitoring of HPV vaccine programs in males.
Monitoring impact in males may be useful even in female only
vaccination program settings, in order to measure the impact on
males obtained through herd protection. As with any vaccination
program, monitoring coverage and adverse events is the founda-
tion of an HPV vaccine program for males. Measuring HPV vaccine
effectiveness in females and males is challenging because of the
variety of factors that need consideration, including different po-
licies (vaccine recommendations, target ages), health system out-
comes (uptake, series completion) and biologic outcomes (infec-
tion, warts, precancer, cancers.) In addition, depending on the
selected biological outcomes, the time frames to detect impact can
range from months to decades [22]. Because of its relative com-
plexity and costs, vaccine effectiveness monitoring through HPV
surveillance is not seen as an essential component of an HPV
vaccination program by the World Health Organization [23]. In-
stead, jurisdictions are encouraged to rely on comprehensive post-
vaccination surveillance systems in settings where infrastructure
and resources allow this [23]. However, despite the challenges,
many developed countries are considering methods to monitor
impact in both females and males to demonstrate program
effectiveness.
To date, aside from anogenital warts, monitoring for HPV vac-
cine impact has focused largely on women. In some settings, cer-
vical screening programs have provided a means to monitor
screen-detected cervical lesions and provide cervical samples for
HPV testing and/or pathology to monitor HPV vaccine impact in
women [24–28]. In men, this surveillance cannot generally be in-
tegrated into established routine screening programs as there are
no recommendations for HPV-associated cancer screening for
males. Although there is much interest in targeted approaches to
screen men (and women) at high risk of anal cancer, the methods
to use, ages to target, optimal treatments and effectiveness of
screening to reduce cancer have not been deﬁned [12].
We outline the objectives of male HPV vaccine effectivenessmonitoring, identify the key challenges to be addressed and con-
sider possible options for such surveillance programs.2. Objectives of male HPV surveillance
The primary objective of any male HPV surveillance program
will be to document changes in the prevalence of HPV infection
and disease in males due to vaccine targeted HPV types occurring
post vaccination, paralleling objectives developed for female sur-
veillance internationally [22,24,26,29–31]. A secondary objective
may be to investigate the additional impact of male vaccination on
female HPV infection and disease. Information on vaccine impact
can support vaccine programs and their sustainability. Dependent
upon the setting and population targeted for vaccination, these
changes may be entirely new (if a vaccine program targets both
sexes from the outset or targets only men who have sex with men)
or may build upon declines already achieved through herd pro-
tection following female only vaccine programs established prior
to gender neutral vaccination.
Options for vaccine impact monitoring in males include HPV
type surveillance in clinician or self-collected specimens, ano-
genital warts, precancer, and cancer surveillance. Within an
overarching HPV vaccine impact monitoring program, different
endpoints can be used to evaluate short, medium and long-term
HPV-related health outcomes of interest. Table 1 presents different
endpoints with reference to existing HPV surveillance programs
for females, how they could be adapted for monitoring in males,
and particular challenges in their assessment.3. Challenges for monitoring HPV vaccine impact in males
Cancer, anogenital warts and recurrent respiratory papilloma-
tosis surveillance can be conducted equally well in male popula-
tions because their diagnosis and reporting in cancer registries and
in clinical records is similar for males and females (Table 1). An-
ogenital wart surveillance has already demonstrated a reduction in
incidence in heterosexual males following female only HPV vac-
cination programs in some countries, reﬂecting herd protection
through reduced transmission from females to male sexual part-
ners [32–34]. The extent of disease reduction in males due to herd
protection is female coverage dependent [34]. This will make
differentiating the impact of male vaccination either introduced
concurrently or as an incremental strategy challenging, particu-
larly if a move from female only to gender neutral vaccination
programs facilitates an overall increase in coverage in both sexes.
Anogenital wart surveillance in MSMmay be especially valuable as
a means of relatively rapidly monitoring the impact of male vac-
cination programs, given that to date female vaccination programs
have not convincingly demonstrated any herd immunity impact in
this population [32]. However vaccine coverage achieved among
MSM might differ from that achieved in other men.
Surveillance approaches for sexually transmitted infections
(STIs) in women include: population based screening using large
population based surveys; venue based screening at STI clinics;
opportunistic testing at laboratories of specimens collected for
another purpose; and, targeted screening of priority populations.
While this has offered opportunities for HPV surveillance in wo-
men, for men HPV surveillance may pose new challenges as there
are not routine clinical screening programs for HPV or HPV-related
cancers in men. HPV type prevalence assessments in males will
rely on new or structured efforts that collect biological specimens.
Surveys in which biomedical specimens from are collected could
include self-collected or provider-collected specimens for HPV
testing of males. For example, the National Health and Nutrition
Table 1
Outcomes for HPV monitoring: existing female strategies, possible male strategies and challenges.
HPV Outcome Existing female methods Male options Challenges (M¼males, F¼ females)n
Genital HPV infection (vac-
cine targeted types and
non-targeted types)
a) HPV typing of liquid based samples ob-
tained from cervical screening [13,56,57]
a) HPV typing of samples collected from
external genitalia (glans, shaft, scrotum),
self collected or clinician collected [60]
1) Representativeness of study population
(FþM, a,b,c,d)
b) HPV typing of self collected vaginal
samples [37,58]
c) HPV typing of urine samples from
i) residual specimens from Chlamydia
screening progams [36]
ii) purpose collected specimens [59]
d) HPV typing from oral specimen (e.g.
rinse)
b) HPV typing of anal swabs [61]
c) HPV typing from oral specimen (e.g.
rinse) [62]
d) HPV typing of urine samples from
i) residual specimens from Chlamydia
screening progams [36]
ii) purpose collected specimens [41]
2) Ensuring consistency of HPV typing methods
over time so that results are comparable (FþM,
a,b,c,d)
3) Availability of vaccination status and sexual
history data from participants (FþM, a,b,c,d)
4) Distinguishing deposition from infection
(FþM,a,b,c,d)
4) Standard collection method not established
(M, a, b)
5) Urine has low sensitivity in males to detect
the presence of genital HPV infection (M,d) and
is therefore not a suitable specimen type for
routine monitoring in males
Genital intraepithelial
neoplasia
a) Trend analysis of CIN2þ in cervical
screening registry data
a) Monitor rates of AIN diagnoses in po-
pulations using hospitalisation data,
health insurance databases or population
based health registry data (Nordic coun-
tries only) Because PIN is very rare and not
screened for, monitoring rates (even
where possible) is unlikely to provide
useful monitoring data.
1) Ecological nature of register data/time
trends in populations of abnormalities. Can be
impacted by trends in diagnosis, participation,
sexual activity etc (F a,b,c þM a)
i) existing registers [63–65]
ii) purpose built registers [66]
b) Trend analysis of vaginal/vulval in-
traepithelial neoplasia in Nordic registers
[22,,67]
b) Use data collected from trials of AIN
screening in MSM in pre vs post vaccine
periods to monitor AIN attributable to
vaccine types over time
c) Vaccine effectiveness estimation
against CIN from registry based data
linkage studies in vaccinated populations
[28,68-70]
d) HPV typing of CIN specimens to de-
termine proportion due to vaccine pre-
ventable types over time [71]
2) Incomplete/inaccurate data linkage (F,c)
3) Lack of population based testing for AIN/PIN
means no register data or stable diagnostic
rates in most countries (M, a)
4) Monitoring rates of AIN due to HPV16/18 in
MSM over time requires research studies being
undertaken of screening at appropriate time
points as HPV typing and screening is not
routine clnical practice (M,b)
Genital warts a) Trend analysis of genital warts/anogen-
ital warts diagnoses in sentinel clinics [32]
[72]
Female surveillance methods also applic-
able to males
1) Ecological nature of time trends of genital
warts in populations. Can be impacted by
trends in treatment modalities, access to health
care services, sexual activity etc (FþM, a,b,c,d,
e,f)
b) Trend analysis of anogenital warts di-
agnosed in general practice [73]
2) Representativeness of study population
(FþM,a,b,c,d)
3) Need to obtain information about sexual
orientation in order to monitor in MSM popu-
lations (M,a,b,c,d,e,f)
c) Trend analysis of diagnoses and treat-
ment in insurance populations [74,75]
d) Trend analysis of national hospitalisa-
tion data [33]
e) Trend analysis of national health reg-
istry data (Nordic [76,77])
f) Vaccine effectiveness estimation
against genital warts from registry based




a) Monitoring hospitalisations over time
[79]
Female surveillance methods (monitoring
of incident cases of RRP) also applicable to
males
1) Rare disease (FþM,a,b,c,d)
2) Ecological nature of time trends (FþM,a,b,c,
d)b) Register based RRP surveillance
(Canada) 3) Usually no RRP surveillance/register estab-
lished prior to vaccination programs to provide
baseline data (FþM,b,c)
c) Rare childhood diseases surveillance
through ENT surgeons and paediatricians
[80] 4) HPV typing of RRP lesions not routine in
many countries (FþM,d)d) Monitoring of HPV types in RRP lesions
Cancer a) Use of cancer registries to monitor rates
of cervical, vagnial, vulval, anal and HPV-
associated head and neck cancers over time
[22]
Female surveillance methods (analysis of
cancer incidence data over time) also ap-
plicable to males.
1) Data quality. In many countries cancer re-
gistries are incomplete, of poor quality or do
not exist. (FþM,a)
2) Long time frame between HPV vaccination
and impact on cancers. (M4F,a)
Add monitoring of penile cancers.
3) Consider systems to record vaccination sta-
tus against cancers - e.g. for verifying and re-
cording vaccination status on cancer registers.
(FþM,a)
4) HPV typing of cancers is not routine- con-
sider development of methods to record on
registers. (FþM,a)
5) May be changes over time in which cancers
are classiﬁed as HPV-related so care is needed
in applying consistent inclusion critreria. Site-
speciﬁc coding for head and neck cancers is
incomplete in some registers. (FþM,a)
Cancer mortality a) Use of cancer registries and cause of
death registers to monitor rates of cervical,
vagnial, vulval, anal and HPV-associated
head and neck cancers over time [22].
Female surveillance methods (analysis of
cause of death data over time) also ap-
plicable to males.
1) Data quality. In many countries cause of
death registries are incomplete, of poor quality
or do not exist. (FþM,a)
2) Long time frame between HPV vaccination
and death from cancers. (M4F,a)
Add monitoring of mortaliy from penile
cancers.
n Letters in brackets refer to the subsections in the adjacent male and female surveillance columns.
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Sexual Attitudes and Lifestyles (NATSAL) in the UK [36] both
provide an opportunity to collect clinical samples appropriate for
HPV testing from participants. Australia does not currently have a
similar population survey infrastructure; therefore, HPV surveil-
lance in Australia is dependent in the short term at least on
dedicated HPV studies where specimens are obtained from clinic
populations or through self-collected sampling from participants
enrolled through in special studies, as has been achieved for HPV
testing in young women [37]. Methods to conﬁrm vaccination
status will need setting speciﬁc consideration dependent upon the
availability of vaccination registers, clinical or patient held records
of vaccination. STI clinics and clinics that serve youth or MSM may
be appropriate sites to obtain genital specimens.4. Site and specimen collection for HPV detection in males
HPV infection prevalence differs signiﬁcantly by anatomic site;
infection prevalence is high at the external genital skin in both
MSW and MSM (and is higher at the anus in MSM than in MSW or
in women) and lowest at the oral epithelium (e.g., HPV 16 pre-
valence in MSW is 6% at external genital skin, 2% at anal canal, and
0.6% at oral epithelium [38]). In pre-licensure efﬁcacy trials, the
quadrivalent HPV vaccine was shown to provide protection against
HPV infection and related lesions at the external genital skin and
anal canal [39,40]. Given these data, and the relatively high pre-
valence of infection at these anatomic sites, the external genital
skin and anal canal are appropriate to consider sampling in post-
vaccine surveillance activities among males.
Male external genital specimens suitable for HPV testing are
not routinely collected for other health purposes. Unfortunately,
the readily obtainable urine specimen has been shown repeatedly
to provide a poor reﬂection of HPV status in males [41–43]. Direct
sampling of the external genital skin and anal canal are required to
accurately estimate HPV infection in men. Several different
methods of sampling the external genital skin have been in-
vestigated; sampling with pre-wetted Dacron swab alone or fol-
lowing mild abrasion of the genital skin, and dry swab sampling of
the external genital skin. In addition, provider sampling and self-
sampling using these methods have been explored. The collective
evidence indicates that abrasive methods are not required in order
to collect a specimen adequate for HPV detection from males [44–
46]. However obtaining suitable specimens still relies on adequate
technique, which may be facilitated by self-collection (allowing
ﬁrmer swabbing) rather than clinician collection. Men may ﬁnd
self -collection more acceptable and less embarrassing [44,47]. A
recent study found self-collection using dry swabs to be more
acceptable to men, quicker to use and less painful, but just as ef-
fective as an emery-wet swab technique for HPV detection [44]
and is being used in some monitoring programs [48]. Anal canal
self sampling has been found to be acceptable to MSM in several
studies and may be a useful sample type for monitoring given the
high prevalence of HPV at this site in this population [49–51]. For
surveillance purposes, whichever sampling and typing methods
are used, the methods should be sufﬁciently sensitive, consistent
over time and ideally consistent with other published studies to
facilitate comparisons. A variety of issues can be considered for
choice of HPV typing methods for males [52]. A pilot surveillance
phase would be helpful to establish that the proposed methods are
feasible, produce valid results, and are acceptable to participants,
so that they can be consistently used for accurate surveillance over
time. A pilot phase can also determine baseline prevalence to in-
form sample size estimates for the particular population. Com-
prehensive sampling of multiple sites with one swab (e.g. shaft of
penis, tip, coronal sulcus, scrotum 7anus) may better reﬂect theoverall HPV burden at the external genitals but may not be needed
for monitoring vaccine impact as long as a consistent method over
time is used [43].5. Assessing reduction in clinical disease
HPV-related diseases such as the pre-cancers and anogenital
warts, are not routinely reportable conditions in most countries
(except in the case of cervical pre-cancers reportable to screening
registers in those countries with registers integrated as part of the
screening program). [22] Furthermore, with an absence of
screening programs for HPV-associated neoplasia to detect pre-
cancers in males, measuring any reduction in these lesions will be
challenging in most settings. Also, where diagnosis of these lesions
occurs in routine practice, these data are not systematically col-
lected in registers or tested for HPV in most settings. Furthermore,
any changes in screening practices for anal cancer would impact
trends in anal pre-cancers lesions (as would changes in cervical
screening programs impact upon apparent cervical pre-cancer
lesion prevalence for women). Following introduction of vaccina-
tion programs, monitoring of HPV types in lesions in high risk
populations, such as MSM and HIV-infected men, may be a sui-
table way to obtain indicators of vaccine impact. This type of
monitoring may best be performed as repeated research studies
over years as a part of formal anal screening evaluation studies
[18] or targeted vaccination evaluations rather than using any
routine population based health data sources. Care needs to be
taken in ascribing HPV types to lesions during such focal surveil-
lance studies in MSM populations, given existing evidence that
HPV detected by anal swabs are frequently of multiple types and
have poor concordance with HPV types that cause focal lesions as
identiﬁed by analysis using laser- capture microdissection [53].
HPV related cancers, such as anal, penile, oropharyngeal can-
cers, are routinely reported in most countries as a part of cancer
registries. Optimally, HPV related cancer rates in males will be
monitored through such cancer registries. However, because non-
cervical HPV-related cancers have an older median age of onset,
the impact of HPV vaccination on cancer incidence among males
will take comparatively longer to observe [54].6. Design considerations for male HPV prevalence surveillance
Approaches to male HPV surveillance will depend upon the
characteristics of the HPV vaccination program (i.e. target age
group, universal approach from commencement or female vacci-
nation ﬁrst, years since commencement, uptake) and infra-
structure for supporting collection of specimens from males. In
many places no HPV prevalence data in young males will exist
prior to male vaccination commencing and this may be a parti-
cular challenge if female vaccination has already been underway
for some years (for example, in Australia and the US). Thus, col-
lection of suitable specimens to establish baseline HPV prevalence
in males, either pre HPV vaccine or following HPV vaccination of
females, would be optimal. For example in Australia, the male
vaccination program commenced in 2013 (following female vac-
cination since 2007). A catch up program was undertaken for boys
up to age 15 years in 2013–2014. In order to compare pre and post
male vaccination HPV prevalence in young males, a study was
designed to commence as soon as possible, given that males aged
17–19 years would be unvaccinated in 2014–2016 (HPV prevalence
reﬂecting impact of female vaccination only) but belong to vacci-
nated cohorts in 2017–2018 (personal communication, Marcus
Chen). Australia is also currently piloting a predominantly clinic
based surveillance system, supplemented with online recruitment
J.M.L. Brotherton et al. / Papillomavirus Research 2 (2016) 106–111110activities, for ongoing HPV prevalence monitoring. (http://www.
health.gov.au/internet/main/publishing.nsf/Content/ohp-HPV.
htm). Resulting HPV prevalence estimates will in turn help de-
termine sample sizes necessary for ongoing monitoring of HPV
prevalence post vaccination. For example, a ﬁve continent study of
HPV prevalence in 16–24 year old males with 1–5 lifetime female
sex partners found HPV 6/11/16 or 18 in 8.8%, 16 or 18 in 5.6% and
HPV16 in just 3.8%. [45]. A baseline prevalence of 5% or lower
would require a large sample size to detect a signiﬁcant decline in
HPV16/18 or 16 alone post vaccination (e.g., in a simple before-
after design with equal sample sizes, 1077 would be required in
each group to detect a fall of 50% (with 80% power, two-sided
test)). If vaccine targeted HPV prevalence is relatively low, due to
broad dissemination of vaccine to females, larger sample sizes may
be needed and/or consideration given to recruiting a sentinel
surveillance population that is relatively high-risk for HPV ex-
posure, such as from an STI clinic setting [47]. Focused efforts in
speciﬁc high-risk populations such as MSM, HIV-infected, or those
attending STI clinics may be optimal in many settings for this
reason [55].7. Conclusion
Monitoring HPV vaccine impact in males will inform policy and
programs worldwide by evaluating the beneﬁts of vaccination
through reduction of infection, disease or cancer in men. There
were be different opportunities and challenges depending on the
outcome and setting. The spectrum of outcomes to be considered
for inclusion in any monitoring plan includes HPV prevalence,
anogenital warts, and cancers. Speciﬁc consideration is needed to
assess opportunities to monitor pre-cancer lesions such as AIN.
Ideally a combination of short term and long term outcome
measures would be included. Surveillance in speciﬁc targeted
populations of MSM and HIV-infected men could be an efﬁcient
use of resources to demonstrate impact.8. Conﬂict of interest statement
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